Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Cash from Financing Activities (2022 - 2025)

Coeptis Therapeutics Holdings has reported Cash from Financing Activities over the past 4 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $2.5 million for Q4 2025, up 235.22% from a year ago — trailing twelve months through Dec 2025 was $13.7 million (up 140.58% YoY), and the annual figure for FY2025 was $13.7 million, up 140.58%.
  • Cash from Financing Activities for Q4 2025 was $2.5 million at Coeptis Therapeutics Holdings, down from $5.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for COEPW hit a ceiling of $6.1 million in Q1 2025 and a floor of -$2.7 million in Q4 2022.
  • Median Cash from Financing Activities over the past 4 years was $1.6 million (2024), compared with a mean of $2.0 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 103.73% in 2023 and later skyrocketed 755.77% in 2024.
  • Coeptis Therapeutics Holdings' Cash from Financing Activities stood at -$2.7 million in 2022, then skyrocketed by 164.1% to $1.8 million in 2023, then plummeted by 58.21% to $731971.0 in 2024, then soared by 235.22% to $2.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $2.5 million (Q4 2025), $5.1 million (Q3 2025), and $125100.0 (Q2 2025) per Business Quant data.